The transaction, slated to finalize in the fourth quarter, carries an immediate financial impact, with Gilead projecting a dilution of its quarterly earnings per share by approximately 79 to 83 cents. The company intends to advance the clinical development of HCXT-2001, exploring its efficacy both as a standalone therapy and in combination with existing assets in its pipeline. Chief Medical Officer Dietmar Berger characterized the acquisition as a vital step in expanding the firm’s inflammation portfolio, citing the potential for a differentiated oral approach to address significant unmet medical needs.
Gilead Bets $1.275B on Oral Treatment for Inflammatory Bowel Disease
Gilead Sciences is moving deeper into the inflammation market with a $1.275 billion cash acquisition of PepStar Therapeutics’ oral IL-23R inhibitor program. This strategic move grants the pharmaceutical giant global rights to HCXT-2001, a candidate currently positioned to potentially transform standard care for patients suffering from inflammatory bowel disease.
Comments (0)
No comments yet. Be the first!